- Home
- RGC vs TAK Comparison
RGC vs TAK Comparison
Compare RGC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- TAK
- Stock Information
- Founded
- RGC 2014
- TAK 1781
- Country
- RGC Hong Kong
- TAK Japan
- Employees
- RGC N/A
- TAK N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- TAK Health Care
- Exchange
- RGC Nasdaq
- TAK Nasdaq
- Market Cap
- RGC 38.6B
- TAK 45.8B
- IPO Year
- RGC 2021
- TAK N/A
- Fundamental
- Price
- RGC $14.66
- TAK $14.68
- Analyst Decision
- RGC
- TAK
- Analyst Count
- RGC 0
- TAK 0
- Target Price
- RGC N/A
- TAK N/A
- AVG Volume (30 Days)
- RGC 2.8M
- TAK 2.2M
- Earning Date
- RGC 06-30-2025
- TAK 07-30-2025
- Dividend Yield
- RGC N/A
- TAK 3.70%
- EPS Growth
- RGC N/A
- TAK N/A
- EPS
- RGC N/A
- TAK 0.45
- Revenue
- RGC N/A
- TAK $30,595,075,281.00
- Revenue This Year
- RGC N/A
- TAK $1.01
- Revenue Next Year
- RGC N/A
- TAK $1.04
- P/E Ratio
- RGC N/A
- TAK $65.09
- Revenue Growth
- RGC N/A
- TAK 7.45
- 52 Week Low
- RGC $0.08
- TAK $12.80
- 52 Week High
- RGC $83.60
- TAK $15.53
- Technical
- Relative Strength Index (RSI)
- RGC 45.32
- TAK 41.31
- Support Level
- RGC $9.39
- TAK $14.93
- Resistance Level
- RGC $30.00
- TAK $15.14
- Average True Range (ATR)
- RGC 6.44
- TAK 0.15
- MACD
- RGC -1.70
- TAK -0.06
- Stochastic Oscillator
- RGC 20.68
- TAK 11.86
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.